Multiple Sclerosis (MS) is a central nervous system autoimmune inflammatory T-cell mediated disease with a relapsing-remitting course in the majority of patients. In this study we performed a high resolution systems biology analysis of gene expression and physical interactions in MS relapse and remission. To this end, we integrated 164 large scale measurements of gene expression in Peripheral Blood Mononuclear Cells (PBMC) of MS patients in relapse or remission and healthy subjects, with large scale information about the physical interactions between these genes obtained from public databases. These data were analyzed with a variety of computational methods.
Introduction
Multiple Sclerosis (MS) is an autoimmune inflammatory T-cell mediated disease, believed to result from a misdirected immune attack against Central Nervous System (CNS) myelin antigens. The damage of myelin in MS leads to neurological dysfunction (1) (2) (3) . MS attacks mainly young adults (usually between ages 20 and 40), and is predominant in women. In northern Europe and the U.S.A. the disease has prevalence of around 100 per 100,000 (2) . Thus, it has a significant socioeconomic impact.
The trigger of the autoimmune process in MS is unknown. It is believed that MS occurs as a result of some combination of genetic, environmental and infectious factors (4) , and possibly other factors like vascular problems (5) . For example, studies of identical twins have demonstrated a concordance of 30% to develop MS (3) suggesting that the genetic background has a relatively limited but significant role in triggering MS.
Symptoms of MS are unpredictable and include among others, motor weakness, loss of balance and muscle coordination, slurred speech, cognitive decline, sensory impairment, and bladder dysfunction.
In 85% of the patients, the disease has a relapsing-remitting (RR) course, which is characterized by the onset or deterioration of the neurological symptoms (relapses), which are followed by partial or complete recovery (remissions). Relapses are the consequence of complex immunological and neurodegenerative processes. They result in the development of new acute inflammatory lesions or the activation of old lesions within the CNS, and are associated with myelin and axonal loss (1, 2, 6) . Accordingly, relapses are the visible clinical expression of the complicated immunopathological mechanisms that occur in the CNS.
As was demonstrated in numerous previous studies , transcriptional profiling of PBMC is a useful tool for identifying gene expression signatures that are related to MS and other autoimmune diseases (for example (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) ; see a more general review in (17)). A possible explanation for the advantageousness of PMBC in this context is the fact that autoreactive immune cells initiate the autoimmune inflammatory process against the corresponding target organs (18) (19) (20) (21) (22) (23) (24) .
The aforementioned studies concerning gene expression in MS were based solely on measurements of mRNA levels. The first stage of gene expression regulation is transcription (i.e. changes in mRNA levels). However, several steps in the gene expression process may be regulated, including transcription, post-transcriptional modifications such as RNA splicing, translation, and post-translational modifications of a protein (25). Thus, studying changes in gene expression should give a very limited and coarse depiction of the regulatory changes that occur in the disease.
Indeed, it was shown that in human and other organisms, the gene mRNA levels explain only about 30% of their protein abundance variance (26, 27) . In addition, mRNA measurements usually suffer from various elements of noise and bias (28).
The goal of the current study is to improve the understanding of the regulatory changes in PBMC in MS, by incorporating in addition to gene expression, prior knowledge about protein-protein (PP) interactions in human. By integrating this additional data we were able to identify genes that undergo regulatory changes in MS, which are not necessarily at the transcription level. It has been shown that such an approach is useful for identifying markers related to metastasis (29) and yields better results compared to analyses based solely on gene expression; the current paper is the first time that such an approach was employed for the analysis of an autoimmune disease. In autoimmune diseases, as in cancer metastasis, many of the regulatory changes are posttranscriptional; thus, such an approach should be beneficial in both cases.
We identified proteins that have many PP interactions with differentially expressed genes (in terms of mRNA levels) in MS compared to healthy subjects, and in MS relapse as compared to MS remission. Such genes have not previously been reported in large scale studies of mRNA levels in MS.
With high probability such genes undergo transcriptional and/or post transcriptional regulation. Thus, our approach enables uncovering suspected transcriptional and posttranscriptional regulatory changes in the disease.
Indeed, as demonstrated in the following sections, we supply a more accurate and comprehensive report of the genes and pathways involved in MS than previously reported.
Results
We analyzed a DNA-microarray gene expression dataset that included a total of 164 subjects. To detect genes that are differentially expressed (in terms of mRNA levels) in the disease, we employed a statistical method which takes into account their demographical parameters and batch effects (Methods). Next, to better understand the molecular mechanisms related to MS, the data of the differently expressed genes was integrated with large scale measurements of protein-protein interactions (PPI) and protein-DNA interactions (PDI, Methods, Figure 1 ).
At all stages, we analyzed two datasets. Each dataset was related to a comparison of two groups of patients or healthy subjects:
1) The first dataset included patients with MS (relapse or remission, 123 patients) that were compared to healthy subjects (41 subjects). This dataset was utilized to understand regulatory processes that appear in both relapse and remission stages of MS.
2) The second dataset included MS patients with relapse (34 patients) that were compared to MS patients with remission (75 patients with active disease, EDSS > 0, Methods). This dataset was used to better understand the regulatory processes that are specific to each stage of the disease.
We named the first dataset MS/healthy and the second dataset Rel/Rem. The properties of these datasets (e.g. age, gender, disease duration of the analyzed patients) appear in Table 1 (see also Supplementary Table 1) .
Differentially expressed genes in MS and their projection on the protein-protein and protein-DNA interaction networks -a global (network-level) view.
Gene expression data was normalized, statistically over/under expressed genes were found in each dataset based on Analysis of Variance (ANOVA (30)), and the False Discovery Rate (FDR; (31) see the Methods section for more technical details regarding the normalizations). We found that 1268 and 938 genes were significant according to ANOVA (p-value ≤ 0.05) in the MS/healthy and the Rel/Rem databases respectively.
In both datasets, no gene passed the FDR criterion based on the ANOVA p-values (see Table 2 for the list of genes with the most significant ANOVA p-value; see also Supplementary Table 2-3 for the entire list of p-values) demonstrating the essentiality of integrating additional information sources in-order to augment the differentially expressed genes signature .
At the next stage, we computed for each gene a p-value that was based on the number and expression levels of genes that have protein interaction with it (but not including mRNA levels of the gene itself). We named this p-value PPI p-value. Genes that have a relatively high number of protein-protein interactions with differentially expressed genes have a higher probability to undergo regulatory changes, possibly post transcriptional, themselves and thus have more significant PPI p-values.
We found that 398 and 257 genes were PPI significant (p-value < 0.05) in the MS/healthy and Rel/Rem databases respectively (see Supplementary Table 2 The first global p-value tests if differentially expressed genes tend to be close to each other in the protein-protein interaction network, as expected for the real biological signal.
We found that this global p-value was significant in the case of the MS/Healthy dataset (p-value = 0.05) but was not significant in the case of the Rel/Rem dataset (p-value = 0.2). The result suggests that the two stages of the disease are relatively similar in terms of the gene expression signature; thus, in general, the differentially expressed genes in the Rel/Rem database do not seem to be clustered in the protein interaction network.
In the second global p-value we checked if the number of genes with significant PPI pvalues is higher than in random networks with similar properties (Methods). This number was significantly higher than expected in randomized networks for the MS/healthy data set (275 in the real data versus 88 in the randomized data; p-value 0.01) but non-significant in the Rel/Rem dataset (Methods).
The third global p-value was related to the number of significantly expressed genes (according to the ANOVA p-value) that also have PPI with other significantly expressed genes (see exact details in the Methods section). We found that in both datasets this number was higher than expected from random permutations with similar properties (69 genes in the real dataset versus a mean of 34 in the randomized gene networks for the MS/healthy dataset, p-value <0.01; and 40 genes in the real dataset versus a mean of 22 in the random networks, p-value <0.05 for the Rel/Rem dataset; Methods). Thus we deduce that p-values based on more refined measures do detect significant global changes also in the Rel/Rem dataset. In the following sections we report additional, more specific and highly significant p-values, related to functional groups of genes and single genes, which are differentially expressed in the Rel/Rem dataset.
Protein-DNA interaction analysis of 111 transcription factors (TFs) and their targets In the MS/healthy dataset, the list of enriched cellular processes that were based on the genes with ANOVA significant p-values includes the following functional groups:
Positive regulation of cell death, Chemotaxis, Inflammatory response (all p-values < 0.0014; see Table 3 ). These cellular processes are known to be key mechanisms in MS.
Almost all the cellular functions that were enriched according to genes with ANOVA significant p-values were also enriched based on genes with PPI significant p-values.
However, the enrichment results according to the PPI significant p-values included additional relevant cellular functions that were not discovered by the ANOVA based enrichment. For example, the cellular functions positive regulation of NF-kappaB transcription factor activity, immune system development, and regulation of caspase activity (all the p-values < 0.0021; see Table 3 ) were uncovered only by the PPI based enrichment.
In the case of the Rel/Rem dataset, the following cellular functions were enriched based on the genes with ANOVA significant p-values: Cell adhesion, Cell migration, Cell-cell signaling, Regulation of cell motion (all the p-values < 0.0007; see Table 3 Table 3 ).
These results demonstrate that many of the regulatory changes in MS cannot be detected based solely on gene mRNA levels; however, incorporating protein-protein interactions can further the discovery of additional relevant regulatory changes in MS.
Genes with significant PPI p-values
The genes with the highest PPI p-values appear in Table 4 The list of genes that passed the FDR test according to the PPI p-value in the Rel/Rem dataset included many genes that related to phosphorylation (for example, PTPRD, Interestingly, when we focused on genes with known SNPs that are associated with MS (32) IL2RA, CD58, IL7R, PLP1, MAG, MOG) , we discovered that many of them have significant p-values (ANOVA or PPI) in at least one of the analyzed databases (Table 4) ; specifically, we found enrichment in the number of genes with SNPs associated with MS among the PPI significant genes in the Rel/Rem dataset (hyper geometric p-value = 0.001).
One interesting gene is IL7R which is a receptor for interleukine 7 (IL7). IL7 has been shown to play a critical role in the V(D)J recombination during lymphocyte development (see (33)). This protein also controls the accessibility of the TCR gamma locus by STAT5 and histone acetylation (see (34)). Knockout studies in mice have suggested that blocking apoptosis is an essential function of this protein during differentiation and activation of T lymphocytes (see (35)). We found that IL7R, which does not have a significant ANOVA p-value, has a significant PPI p-value in the Rel/Rem dataset (p-value = 0.00003), but not in the MS/healthy dataset. Thus, this result may suggest that protein levels of IL7R tend to change between relapse and remission periods of MS, even though no change is observed at the mRNA level of this gene.
Sub-networks of genes with both ANOVA and PPI significant p-values
Next we analyzed the specific set of genes that have both ANOVA and PPI significant pvalues. We also considered the protein-protein interactions between these genes (Methods). The resultant protein interaction networks corresponding to these genes appear in Figure 3 
Clusters of genes with both ANOVA and PPI significant p-values
We clustered the sub-networks mentioned in the previous sub-section to find modules (clusters) of genes with relatively more protein-protein interactions between them ( (36) Methods). The resultant networks and the clusters appear in Figure 3 (for the MS/healthy dataset) and Figure 4 (for the Rel/Rem dataset). We verified that the modularity of the resultant clustering is higher than in random networks with similar properties (p-value < 0.01; see details in the Methods section) suggesting that these clusters indeed have biological significance.
The MS/healthy network includes many apoptotic genes and modules that will be discussed in details in the following section. One striking module includes the cytokine IL1B and its receptor, which are over-expressed in MS. IL1 is known to have an important role in activation of lymphocyte proliferation. Specifically, it induces TNFalpha release by endothelial cell, proliferation of CD4+ cells, IL-2 production, costimulates CD8+/IL-1R+ cells, induces proliferation of mature B-cells and immunoglobulin secretion, induces IL-6 and GCSF secretion, and stimulates expression of Fibroblast Growth Factor (FGF) and Epidermal Growth Factor (EGF). In addition, it was found that MS patients tend to have polymorphisms in this gene and its receptor (37-39).
The Rel/Rem network includes modules related to phosphorylation, the growth factor receptors (EGFR), and cell adhesion.
The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is a hub in one of the modules. EGFR (and some of the proteins interacting with it) is over expressed (in terms of mRNA levels) in relapse relative to remission. EGFR signaling is initiated by ligand binding to the extra-cellular domain of EGFR, and following activation, phosphorylation of cytoplasmic substrates occurs, and a signaling cascade is launched.
As a result many cellular responses are derived. Specifically, there are changes in gene expression, cytoskeletal rearrangement, anti-apoptosis, increased cell proliferation, and adhesion. The EGFR cluster is enriched with genes related to adhesion (p-value 0.03; Figure 4) ; thus, the genes that appear in the EGFR cluster suggest that in our context (relapse vs. remission in MS), EGFR mainly plays an important role in adhesion.
Pathways analysis of genes with significant p-values (ANOVA and PPI)
In order to better understand the molecular mechanisms that are involved in MS/healthy signatures, we combined the genes with significant ANOVA p-values with those with significant PPI p-values, and analyzed them with Ingenuity software (http://www.ingenuity.com). We considered the canonical pathways of Ingenuity and found that the most striking biological pathways that were enriched with these genes were related to IL1-IL8 induced inflammation (p=4.7*10 -19 ; Figure 5A ) and suppression of FASL and P53 dependent apoptosis (p=1.1*10 -12 ; Figure 5B ). This last mechanism is also supported by the significant over-expression of IL1A and Ap1 genes. In our context, the most imperative result of IL8 activation is the upregulation of matrix metalloproteinase (MMP2 and MMP9), which is involved in the blood brain barrier damage mechanism in multiple sclerosis. The activation of inflammatory cellular response in the MS/healthy signature was also demonstrated by the over-expression of the CXCR4 signaling mechanism. As can be seen in Figure 5A ; the CXCR4 receptor and its specific CXCL12 chemokine were over-expressed. This overexpression should lead to an increased phosphorylation of multiple focal adhesion components.
The down-regulation of apoptotic mechanisms in multiple sclerosis have been demonstrated in previous studies (see, for example, (40)). Here by combining gene expression and proteinprotein interactions we were able to reveal more precisely the mechanisms of apoptosis deficiency in the MS/healthy signature ( Figure 5B Figure 5B ). In addition, we found clues that suggest that the p53 signaling pathway is also suppressed in MS: first, as we previously mentioned, we found that p53 is under-expressed; second, we found that p53 masters regulatory proteins such as MDM2, WTN1, p300, PCAF, which have highly significant PPI p-values; third, we found that cJUN, that is known as an antagonist of p53, is over-expressed in MS. Downstream negative regulators of cell cycle, like retinoblastoma 1 (RB), were also over-expressed. Thus, the suppression of immune cell's apoptotic mechanisms could lead to expansion of autoimmune cell clones and maintenance of autoimmunity.
The Rel/Rem signature ( Figure 5C ) characterized by activation of lymphocyte migration mechanisms (p<5.7*10 -4 ) includes a large group of significantly overexpressed cytokines and chemokines (according to the ANOVA test). Specifically, the set of over-expressed genes in the Rel/Rem dataset included the protein CCL14, a cytokine which induces alterations in intracellular calcium concentrations, enzymes released in monocytes and the chemokine CCBP2. These proteins physically interact with each other and are critical for the recruitment of effector immune cells to the inflammation site ( Figure 5C , see, for example, (41, 42) ).
The activation of chemotaxis of lymphocytes and monocytes is demonstrated by the over-expression of members of the MIPI family such as CCL15, which induces changes in intracellular calcium concentrations, and acts via the CCR1 receptor ( Figure 5C ; see, for example, (41, 42) ).
An important chemokine which is over-expressed in Rel/Rem is CCL22 ( Figure 5C ).
It plays a role in trafficking dendritic cells and natural killer cells to the inflammatory sites of monocytes, and chronically activated T lymphocytes. It also displays a mild activity in primary activated T lymphocytes, though has no chemoattractant activity for neutrophils, eosinophils and resting T lymphocytes (see, for example, (41, 42) ).
Another piece of evidence that supports lymphocyte activation in Rel/Rem is the over-expression of CCL12 ( Figure 5C ), which is known to play a role in the pathogenesis of diseases that are characterized by monocytic infiltrates, such as psoriasis, rheumatoid arthritis and multiple sclerosis (see, for example, (43) (44) (45) ).
In addition we found that the VNT molecule, which is found in serum and tissues, and promotes cell adhesion and spreading, is over-expressed in acute relapse ( Figure 5C ).
We also uncovered that acute MS relapse is characterized by stimulation of proinflammatory molecules such as MMP1 and ALOX15 ( Figure 5C ; Supplementary Table 3) .
To complete the picture of lymphocyte activation and monocyte trafficking in inflammatory sites, we report a few additional relevant proteins with significant PPI p-values ( Figure 5C ). This set of proteins includes ( Figure 5C , Supplementary Table 3) IL2R, CXCR4 -a receptor for CCL12, and the focal adhesion kinase (P38MAPK). In addition, it incorporates CD44 ( Figure 5C ), a cell-surface glycoprotein that is involved in cell adhesion and migration, as well as interaction with other ligands, such as osteopontin, collagens, and MMPs. CD44 also binds to chemokines in the intracellular matrix. Interestingly, the receptor of TGFB (PDGFRA (46)), which is an upstream regulator that increases the expression of CCL12 and CCBP2, was overexpressed in the Rel/Rem database as well ( Figure 5C ).
Discussion
In this study, we reported the first systems biology study of gene expression in MS patients under remission and relapse, encompassing 164 large scale measurements of gene expression in PBMC, including clinical and demographical characteristics of the patients, batch effects, and physical interactions between proteins. Using this approach we were able to report the regulatory changes that occur in the disease with a much higher resolution than before (see, for example, (8, 12) ). The results that are reported in this study can be classified to three major levels of resolution: global, pathways and gene groups, and single genes.
At the global level, when considering the expression levels of all the genes and the physical interactions between them, we show that there is a strong global signal related to the disease in the MS/Healthy dataset. Even though there are clear differences between the two disease stages (relapse and remission), and despite the fact that there are specific genes and pathways that are differentially expressed between the two stages of the disease, we discerned a considerably weaker global signal in the Rel/Rem dataset.
Thus, roughly speaking most of the MS gene expression signature remains relatively constant in relapses and remissions.
At the pathway and gene modules level, the current study includes a detailed report of modules and pathways that are involved in the disease (MS/Healthy dataset) and its two stages (Rel/Rem dataset), including the exact set of relevant proteins, and the interaction mechanisms amongst them (see that includes only genes with significant PPI and/or ANOVA p-values). Previous papers (e.g. (8, 12 )) included only a high level report of the pathways that appear to be related to the disease (e.g. T-cell activation, apoptosis, and inflammation). Thus, the pathways outlined in this paper improve our understanding of the disease phenotypes at the signaling pathways level. For example, we found that epidermal growth factor receptor (EGFR) is a 'hub' which interacts with many ANOVA significant genes in the Rel/Rem database, possibly to promote improved adhesion. Thus, it is plausible that the gene expression of the EGFR sub-network is a good candidate for relapse prediction.
At the single gene level, we employ novel statistical analyses that overcome some of the biases related to gene expression analysis, and the fact that many of the regulatory mechanisms are not transcriptional. Thus, we detail a robust list of potential biomarkers of the disease in PBMC (see Tables 2,4 and supplementary tables 1 -3,8-9) . To the best of our knowledge, many of these genes are novel in this context, and have not been reported in previous studies (e.g. (8, 12) ). For example, to the best of our knowledge, the genes SMAD3, RB1, FOS, TP53, BRCA1, TBP with significant p-values in the MS/healthy dataset (see Table 2 ), and the genes PTPRD, PDGFRB, STAT5A, PTPRF, PPFIA1, PTPRS, PPFIA2, SCNN1B with significant p-values in the Rel/Rem dataset, (see Table 2 ) are novel potential biomarkers in the MS context.
Finally, since gene expression in PBMC has been utilized in the study of other autoimmune diseases (see, for example, (7, 15, 16) ), the approach employed in this study can be useful in the case of these diseases as well.
Material and Methods

Population Study
The clinical and demographical characteristics of each of the analyzed dataset (MS/Healthy and Rel/Rem) appear in Table 1 .
In the Rel/Rem dataset we did not include patients whose Expanded Disability Status Scale (EDSS ) (47) was zero.
All the MS patients were diagnosed with definite MS according to the McDonald criteria (48) . MS relapse was defined as the onset of new objective neurological symptoms/signs or the aggravation of existing neurological disability, not accompanied by metabolic changes, fever or other signs of infection, and lasting for a period of at least 48 hours accompanied by objective change of at least 0.5 in the EDSS score. Confirmed relapses and EDSS scores were recorded consecutively.
RNA isolation and microarray expression profiling in MS
PBMC were separated on Ficol-Hypaque gradient, total RNA was purified, labelled, hybridized to a Genechip array (HU133A-2) and scanned (Hewlett Packard, GeneArray-TM scanner G2500A) according to the manufacturer's protocol (Affymetrix Inc, Santa Clara, CA, USA).
The normalization and analysis of the gene expression datasets
We used the Sheba MS center recorded computerized clinical follow up and blood gene expression measurements dataset. This dataset includes information regarding clinical variables such as: age, gender, and EDSS at time of blood sampling.
The following steps of the data analysis were performed by MATLAB: 
The drug regimen of each patient
Supplementary Table 1 includes the drug regimen of each patient during the month of blood withdrawal (last column). We found that differing treatment is not a variable that has a significant effect on the gene expression pattern: The Spearman ranked correlation between the ANOVA p-values of all the genes when considering only the untreated patients vs. the ANOVA p-values when considering all the patients is close to perfect (r = 0.943); i.e. genes that are relatively more significant based on the untreated group are also more significant based on the entire group of patients (roughly speaking the ranking of the genes' p-values does not change).
However, when we considered all the patients there we uncovered 16% more significant genes (the statistical power increases). Thus, we decided to employ all the patients.
The Protein-Protein interaction network of Human
The human protein-protein interaction network was gathered from public databases (49, 50) and from recently published papers (51, 52) . The final reconstructed network includes 7915 proteins and 28972 protein-protein interactions (a subset of 6850 proteins and 25931 protein-protein interactions appears in the analyzed chips).
Protein-DNA interaction network of Human
This network was downloaded from the TRED database (53). It includs 112 TFs, 2964
proteins that are regulated by these TFs, and a total of 7298 protein-DNA interactions.
When considering only the genes that appear on the analyzed Genechip array, there are 111 TFs, 6069 proteins that are regulated by the TFs and a total of 5787 protein-DNA interactions.
Gene Specific P-values based on the Protein-Protein Interaction Network
For each protein in the protein-protein interaction network, we computed a hypergeometric p-value that was based on the number of ANOVA significant proteins that interact with it, the total number of ANOVA significant, and the topology of the To get a more refined p-value we repeated iteratively (till convergence) on the procedure described above in the following way:
In iteration k compute for each gene a PPIk p-value that is based on the PPIk-1 p-values computed in the previous iteration using the formula above, with the only change being we replace ANOVA significant genes with genes that are PPIk-1 significant (i.e. is the total number of proteins with significant PPIk-1 p-values and is the number of protein interactions with gene that have significant PPIk-1 p-value).
In this paper we considered three sets of genes:
A) Genes that satisfy two conditions: 1) significant ANOVA p-value and 2) significant PPI-network p-value. Such genes appear in Figures 3-4 .
B) Genes that satisfy only condition 2). Such genes appear in the left sides of Tables   2 and 3 . C) Genes that satisfy only condition 1). Such genes appear the right sides of Tables 2 and 3 .
A global p-value related to the total number of protein-DNA
interactions
In this subsection, we describe a global p-value which is related to the number of genes with ANOVA significant p-values, such that each of them is regulated by at least one ANOVA significant Transcription Factor (TF).
The aforementioned global p-value related to the number of genes was computed as follows:
Repeat 100 times:
1. Randomly choose a subset of genes of size .
2. Assume that the subset of genes that was chosen in 1 includes the ANOVA significant genes, and compute the number of genes that are ANOVA significant and are regulated by at least one ANOVA significant TF.
3. Compute the empirical probability (frequency) that the number of genes with ANOVA significant p-values that are regulated by at least one TF which is ANOVA significant, obtained in a random network, is larger (or equal) than the number of such genes in the original network.
A global P-value for the number of genes with significant PPInetwork p-values
A global p-value which is related to the number of genes with significant PPInetwork p-values was computed as follows:
2. Assume that the subset of genes that was chosen in 1 includes the ANOVA significant genes, and compute for all genes the PPI p-values mentioned above.
3. Compute the empirical probability (frequency) that the number of genes with significant PPI p-values obtained in the random network is larger (or equal) than the number of genes with significant PPI p-values obtained in the original network.
A global P-value for the distance between ANOVA significant genes in the PPI-network
The aim of the global p-value described in this sub-section was to demonstrate that genes with ANOVA significant p-values tend to be close to other genes with ANOVA significant p-values in the protein-protein interaction network. Therefore the observed changes in the gene expression are not random.
This global p-value was computed as follows:
1.Find for each gene that is ANOVA significant, the distance to the closest gene in the protein-protein interaction network that is also ANOVA significant.
Compute the mean distance.
2.Randomly select a subset of genes and assign them to the nodes of the PPInetwork such that the degree distribution of these nodes will be identical to the degree distribution of ANOVA significant nodes in the original graph.
3.Find the mean distance between each of the random ANOVA significant nodes and its closest neighbor, and compute the mean distance 4.Compute the empirical probability (frequency) that the random network has a smaller (or equal) mean distance than the mean distance in the original one.
Clustering the Differentially Expressed Networks
The clustering of differentially expressed networks was performed by the Newman algorithm (36) for finding communities in biological networks. The algorithm was implemented in MATLAB. This algorithm detects sub-sets (clusters) of proteins that include relatively many protein interactions between them (compared to other parts of the network). By definition, a network is modular if it can be divided to modules/sub-networks with a large number of protein-protein interactions between proteins within the same module, and less protein-protein interactions between proteins that reside in different modules.
We analyzed the protein-protein interaction network consisting only of genes with both significant PPI and ANOVA p-values, with the aforementioned Newman algorithm We used the modularity score that is described in the work of Girvan and Newman, (36) . To evaluate the significance of the modularity score of the resultant clustering, we compare it to the modularity score of randomized inputs as follows:
Let n denote the number of nodes (proteins) in the original network. Let u1, v1, u2, and v2 denote four proteins (nodes) in the network and let (u1,v1) denote protein-protein interaction between proteins u1 and v1.
Each random network was generated in the following way:
1. Start with the original protein-protein interaction sub-network.
2. Repeat 10*n times on the following steps:
a. Choose a random pair of edges (u1,v1) and (u2,v2) in the network.
b. Replace them with a new pair of edges (u1,v2) and (u2,v1) .
GO enrichment:
GO 
FDR test for the p-values of single genes
In this case, we considered the nonparametric approach of (31) with a threshold of q = 0.05.
Fold Change
To estimate the fold change in one condition versus the second (e.g. relapse vs.
remission) while taking into account the batch effects and additional variables, we performed a multivariate linear regression (see, for example, (55) Figure 1. Flow diagram of the analysis performed in this study. 37.7 +-11.14 6.8 +- 
Legends to Figures
